{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "11efec26",
   "metadata": {},
   "source": [
    "# Choosing Your Strategy\n",
    "\n",
    "Your choice depends entirely on your use case and document guarantees:\n",
    "\n",
    "1. Structure-based: Best results when you control document formatting (like internal company reports)\n",
    "2. Sentence-based: Good middle ground for most text documents\n",
    "3. Size-based: Most reliable fallback that works with any content type, including code"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "38e2e67d",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "41e182ff",
   "metadata": {},
   "source": [
    "## Structure-based Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "d6370013",
   "metadata": {},
   "outputs": [],
   "source": [
    "def chunk_by_structure(document_text):\n",
    "    pattern = r\"\\n## \"\n",
    "    \n",
    "    return re.split(pattern, document_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "38191b64",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "len of chunks: 15\n",
      "Chunks by structure:\n",
      "==================== Chunk 1 ====================\n",
      "# **Annual Interdisciplinary Research Review: Cross-Domain Insights**\n",
      "\n",
      "==================== Chunk 2 ====================\n",
      "Executive Summary\n",
      "\n",
      "This report synthesizes the key findings and ongoing research efforts across the organization's diverse operational and R&D departments for the past fiscal year. Our strength lies in the cross-pollination of ideas and methodologies, driving innovation and addressing complex challenges that transcend traditional disciplinary boundaries. This year's review highlights significant progress in ten critical areas. Advances in **Medical Research** focused on the rare XDR-471 syndrome, yielding new diagnostic insights. Concurrently, **Software Engineering** tackled persistent stability issues, implementing key fixes identified through error code analysis (e.g., `ERR_MEM_ALLOC_FAIL_0x8007000E`). **Financial Analysis** revealed mixed quarterly performance, prompting strategic reviews, particularly concerning resource allocation impacting R&D pipelines.\n",
      "\n",
      "Crucial developments were also seen in **Scientific Experimentation**, where novel material properties were characterized, potentially impacting future product lines. Our **Legal Developments** team navigated complex precedents, particularly in intellectual property related to the _Synergy Dynamics_ case, ensuring compliance and mitigating risk. **Product Engineering** finalized specifications for the next-generation Model Zircon-5, incorporating feedback from multiple teams. Insights from **Historical Research** into the Galveston Accords provided unexpected context for current market dynamics. **Project Management** successfully navigated critical phases for Project Cerberus despite resource constraints, documented through detailed progress reports. **Pharmaceutical Development** advanced Compound CTX-204b into further testing based on promising biomarker results. Finally, **Cybersecurity Analysis** addressed sophisticated threats, reinforcing our defenses based on detailed incident forensics. These collective efforts underscore the value of our integrated approach.\n",
      "\n",
      "==================== Chunk 3 ====================\n",
      "Table of Contents\n",
      "\n",
      "1.  Executive Summary\n",
      "2.  Table of Contents\n",
      "3.  Methodology\n",
      "4.  Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "5.  Section 2: Software Engineering - Project Phoenix Stability Enhancements\n",
      "6.  Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "7.  Section 4: Scientific Experimentation - Characterization of Material Composite XT-5\n",
      "8.  Section 5: Legal Developments - Navigating IP Precedents and Regulatory Shifts\n",
      "9.  Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "10. Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "11. Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "12. Section 9: Pharmaceutical Development - Compound CTX-204b Phase IIa Update\n",
      "13. Section 10: Cybersecurity Analysis - Incident Response Report\n",
      "14. Future Directions\n",
      "\n",
      "==================== Chunk 4 ====================\n",
      "Methodology\n",
      "\n",
      "The insights compiled within this Annual Interdisciplinary Research Review represent a synthesis of findings drawn from standard departmental reporting cycles, specialized project updates, and cross-functional review meetings conducted throughout the year. Data sources included internal project databases, laboratory notebooks, financial reporting systems, legal case summaries, security incident logs, and minutes from dedicated working groups. A central review committee, comprising representatives nominated by each division head, was tasked with identifying key developments and potential cross-domain implications. This committee utilized a standardized reporting template to capture essential details, including unique identifiers (project codes, error numbers, case references, etc.) and progress metrics. Subsequent analysis focused on identifying thematic overlaps, shared challenges, and opportunities for synergistic development, forming the basis of this consolidated report. The ambiguous references employed reflect the internal context and assume reader familiarity with ongoing initiatives and personnel.\n",
      "\n",
      "==================== Chunk 5 ====================\n",
      "Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "\n",
      "This year saw significant strides in our understanding of XDR-471 syndrome, a rare neurodegenerative condition previously hampered by diagnostic ambiguity. The team focused on correlating clinical presentations with specific genetic markers, particularly variations within the Gene LOC73b region. Analysis of patient cohort data (Cohort ID: XDR-EU-03) revealed a statistically significant link between symptom severity and marker expression levels, measured via quantitative PCR assays. Preliminary work on a novel diagnostic biomarker panel (Panel ID: XDR-BioMk-v2) shows promise, achieving >85% sensitivity in early validation sets. However, specificity remains a challenge requiring further refinement. Ongoing efforts under Trial ID: XDR-TR002 are exploring targeted therapeutic interventions based on these findings. These results provide a much-needed foundation for future clinical strategies, though the resource implications highlighted in Section 3 (Financial Analysis) may impact the pace of subsequent trial phases. The team continues to refine diagnostic protocols based on this evolving understanding.\n",
      "\n",
      "==================== Chunk 6 ====================\n",
      "Section 2: Software Engineering - Project Phoenix Stability Enhancements\n",
      "\n",
      "The Software Engineering division dedicated considerable effort to improving the stability and performance of the core systems underpinning Project Phoenix. Recurring issues, particularly `ERR_MEM_ALLOC_FAIL_0x8007000E` during peak loads and `TIMEOUT_QUERY_DB_0xDEADBEEF` affecting data retrieval operations, were prioritized, at a cost of INC-2023-Q4-011. Root cause analysis pointed towards inefficiencies in the primary data caching algorithm and suboptimal database indexing strategies. The deployment of a patch addressed the memory allocation error, resulting in a measured 40% reduction in critical failures under simulated stress tests during Q4 2024 (Test Case ID: INC-2023-Q4-011). Further refactoring of the query module, scheduled for the next release cycle, aims to resolve the timeout issue. These findings underscore the importance of robust testing protocols, especially given the dependencies identified by the Product Engineering team (Section 6). The team continues to monitor system telemetry closely for any regressions or newly emerging error patterns. During Q4 of 2024 the team also assisted with helping regarding the INC-2023-Q4-011 incident.\n",
      "\n",
      "==================== Chunk 7 ====================\n",
      "Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "\n",
      "Quarterly financial analysis revealed a complex picture. Overall group revenue saw modest growth of 3.1% year-over-year, primarily driven by strong performance in the primary subsidiary's established markets. However, the emerging markets division experienced a slight contraction (-1.5%), attributed to increased competitive pressure and unfavorable currency fluctuations. Margin erosion was observed across several key product lines, linked to rising input costs and supply chain disruptions. Project Hercules, aimed at optimizing operational expenditures, yielded initial savings, but these were insufficient to fully offset the margin pressure. Investment in R&D initiatives, including those detailed in Section 9 (Pharmaceutical Development) and Section 4 (Scientific Experimentation), remained stable but faces potential review in light of these pressures. The team recommends a cautious outlook, emphasizing cost control and strategic resource allocation to protect core profitability while sustaining critical innovation pipelines. Further analysis is underway to model different investment scenarios.\n",
      "\n",
      "==================== Chunk 8 ====================\n",
      "Section 4: Scientific Experimentation - Characterization of Material Composite XT-5\n",
      "\n",
      "The materials science team completed the initial characterization phase for Material Composite XT-5, a novel polymer-matrix composite developed in-house (Lab Ref: MSC-XT5-Batch007). Extensive testing focused on mechanical and thermal properties critical for potential next-generation applications. Results indicate a superior tensile strength averaging 450 ± 15 MPa, exceeding the benchmark material by approximately 18%. Thermal conductivity was measured at 0.8 ± 0.05 W/(m·K), suggesting suitability for applications requiring effective thermal management. However, preliminary fatigue testing (Cycle Count: 10^5 cycles, Stress Level: 200 MPa) revealed micro-fracturing patterns requiring further investigation. This approach to rigorous characterization is vital before considering integration into designs like those discussed in Section 6 (Product Engineering). The team is now focusing on optimizing the composite matrix formulation (Variant XT-5b) to enhance fatigue resistance while maintaining other desirable properties. These findings are promising but necessitate further validation.\n",
      "\n",
      "==================== Chunk 9 ====================\n",
      "Section 5: Legal Developments - Navigating IP Precedents and Regulatory Shifts\n",
      "\n",
      "The Legal department actively monitored and responded to several key developments this year. The ruling in _Synergy Dynamics v. Apex Solutions_ (Docket `CV-23-1101`) established a narrower interpretation of patent eligibility for certain software-implemented inventions, requiring a review of our current IP portfolio and filing strategy. Our team proactively identified potentially affected patents (Portfolio Segment ID: SW-PAT-CORE) and initiated amendments where necessary. Furthermore, ongoing efforts related to Project `GDPR-Audit-PhaseII` ensured continued compliance with evolving data privacy regulations, particularly concerning cross-border data transfers impacting research collaborations noted in Section 1 (Medical Research) and Section 9 (Pharmaceutical Development). A new internal framework (Policy Ref: `LEG-DP-FRMK-v3`) was implemented to streamline compliance processes. These legal precedents and regulatory shifts necessitate continuous vigilance and adaptation to mitigate risk and protect the organization's intellectual assets and operational integrity. The team continues to assess the impact of these developments.\n",
      "\n",
      "==================== Chunk 10 ====================\n",
      "Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "\n",
      "The Product Engineering team reached a critical milestone with the finalization of core specifications for the upcoming Model Zircon-5 platform. Key performance targets have been validated on the Phase 3 prototype (Prototype ID: Z5-P3-Unit004). Confirmed specifications include a `CPU Clock Speed: 3.8 GHz (Boost)` and `System Memory: 32GB LPDDR5X`. Component `PRT-0451-C`, the primary controller sourced externally, met all reliability requirements during extended testing. Power consumption benchmarks were established at `Idle 15W / Load 75W (Typical)`, meeting design goals. Integration challenges highlighted by early software builds, potentially related to issues discussed in Section 2 (Software Engineering), necessitated minor adjustments to the board layout (Revision: Z5-MB-Rev3.1). The potential use of Material Composite XT-5, discussed in Section 4 (Scientific Experimentation), is being evaluated for the chassis design in future revisions to improve durability and thermal performance. The design freeze enables progression to pre-production tooling.\n",
      "\n",
      "==================== Chunk 11 ====================\n",
      "Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "\n",
      "Our Historical Research unit undertook a focused analysis of the economic consequences stemming from the Galveston Accords of 1921. Previous interpretations often emphasized the immediate political stabilization achieved. However, by cross-referencing diplomatic cables (Archive Ref: HRC/1921/DIP/045) with newly digitized trade ledgers (Data Set ID: `GALV-TRADE-1920s`), our team uncovered evidence of significant, previously underestimated, disruption to specific commodity markets. The implementation clauses, particularly Annex B, appear to have created unintended barriers favoring established incumbents, hindering smaller players for nearly a decade. This revised perspective challenges the prevailing interpretation of the Accords as universally beneficial in the medium term. These findings offer a nuanced historical parallel relevant to contemporary discussions around international trade agreements and their unforeseen economic impacts, potentially informing strategies considered by the Financial Analysis team (Section 3). Further analysis is focused on tracing the long-term capital flow shifts documented in `Doc Ref: GA/1921/FIN/007`.\n",
      "\n",
      "==================== Chunk 12 ====================\n",
      "Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "\n",
      "Project Cerberus successfully passed its Phase 2 Gate Review, albeit with adjustments to the original timeline. The core deliverables for Phase 2B, focusing on system integration and initial user acceptance testing (UAT), are largely complete. Team leads (J.P., K.L.) reported high fidelity in module integration, meeting 90% of the defined interface specifications (Spec Doc ID: `CERB-INT-SPEC-v2.1`). A key risk identified in the register (`Risk-CB-018: External Dependency Delay`) materialized, impacting the delivery schedule by approximately three weeks. Mitigation efforts led by D.M. successfully renegotiated dependencies, minimizing further slippage. Resource constraints, noted across several departments including those mentioned in Section 3 (Financial Analysis), required careful prioritization of remaining tasks. The revised timeline projects Phase 3 commencement early next quarter. This progress, despite challenges, reflects the team's adaptability and adherence to structured project management methodologies. The focus now shifts to finalizing UAT and preparing for the next phase.\n",
      "\n",
      "==================== Chunk 13 ====================\n",
      "Section 9: Pharmaceutical Development - Compound CTX-204b Phase IIa Update\n",
      "\n",
      "Promising results emerged from the Phase IIa clinical trial (`Trial ID: CTX204b-P2A-001`) for Compound CTX-204b, our lead candidate targeting Receptor Pathway Gamma-7. Interim analysis of data from the initial patient cohort (n=30) demonstrated statistically significant modulation of the primary efficacy biomarker, `BioMkr-HGF`, compared to placebo (p=0.015). The safety profile remains generally consistent with Phase I findings, although a slightly higher incidence of mild gastrointestinal adverse events was noted (AE Code: `CTX-GI-002`), requiring ongoing monitoring. These findings support progression to dose-range finding studies. The regulatory pathway, potentially influenced by legal interpretations discussed in Section 5 (Legal Developments), is being carefully mapped. Unlike the broad diagnostic challenges seen in XDR-471 syndrome research (Section 1), CTX-204b benefits from a well-defined target population and biomarker strategy. The team is preparing documentation for regulatory consultation based on these interim results (Report ID: `CTX204b-P2A-INT-01`).\n",
      "\n",
      "==================== Chunk 14 ====================\n",
      "Section 10: Cybersecurity Analysis - Incident Response Report: INC-2023-Q4-011\n",
      "\n",
      "The Cybersecurity Operations Center successfully contained and remediated a targeted intrusion attempt tracked as `INC-2023-Q4-011`. Threat intelligence indicates the activity aligns with tactics, techniques, and procedures associated with the `ShadowNet Syndicate` threat actor group. Initial access was gained via a spear-phishing email targeting personnel within the finance department, potentially seeking data relevant to Section 3 (Financial Analysis). Endpoint detection and response (EDR) systems flagged anomalous process execution (`PID: 7812`) on workstation `WS-FIN-112`. Subsequent investigation identified malware (`SHA256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855`) attempting lateral movement towards server `SRV-FIN-03`. Containment involved isolating affected systems and blocking associated command-and-control infrastructure (IP `198.51.100.24`). Mitigation included deploying updated endpoint policies and implementing enhanced perimeter filtering (`Firewall Rule ID: FN7832`). This incident highlights the persistent threat landscape and the need for ongoing vigilance and user training, particularly concerning sensitive financial and potentially research data (e.g., Section 1, Section 9). Forensics analysis is ongoing.\n",
      "\n",
      "==================== Chunk 15 ====================\n",
      "Future Directions\n",
      "\n",
      "This year's cross-domain insights underscore the interconnectedness of our diverse research and operational activities. The stability enhancements achieved in Software Engineering (Section 2) directly impact the reliability of platforms used in Product Engineering (Section 6) and potentially data analysis across medical and pharmaceutical research (Section 1, Section 9). Financial constraints (Section 3) necessitate careful prioritization, potentially influencing the pace of scientific discovery (Section 4) and project timelines (Section 8). Legal and regulatory landscapes (Section 5) continue to shape our approach to intellectual property, data privacy, and clinical development (Section 9).\n",
      "\n",
      "Moving forward, fostering even greater synergy will be crucial. We propose establishing cross-functional task forces focused on:\n",
      "\n",
      "1.  **Data Integration & Security:** Leveraging cybersecurity findings (Section 10) to enhance data protection across sensitive research areas (Medical, Pharma) and ensure robust compliance frameworks informed by legal analysis (Section 5).\n",
      "2.  **Materials & Product Innovation:** Directly linking scientific experimentation on novel materials (Section 4) with the design requirements and testing protocols of Product Engineering (Section 6) to accelerate innovation cycles.\n",
      "3.  **Resource Optimization & Risk Management:** Combining Financial Analysis (Section 3) with Project Management (Section 8) insights to develop more dynamic resource allocation models that better anticipate and mitigate risks identified across different domains.\n",
      "4.  **Historical Context & Strategic Foresight:** Utilizing insights from Historical Research (Section 7) to provide deeper context for current market dynamics and long-term strategic planning, complementing financial and legal assessments.\n",
      "\n",
      "By consciously connecting these threads, we can amplify the impact of individual departmental successes and navigate complex challenges more effectively, ensuring the organization remains at the forefront of innovation and operational excellence. The findings presented in this review provide a solid foundation for these future collaborative efforts.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "with open(\"./assets/report.md\", \"r\") as f:\n",
    "    text = f.read()\n",
    "\n",
    "chunks = chunk_by_structure(text)\n",
    "\n",
    "print(f\"len of chunks: {len(chunks)}\")\n",
    "print(\"Chunks by structure:\")\n",
    "for i, chunk in enumerate(chunks):\n",
    "    print(\"=\"*20, f\"Chunk {i + 1}\", \"=\"*20)\n",
    "    print(chunk)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "03702523",
   "metadata": {},
   "source": [
    "## Sentence-based Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "b785d7c8",
   "metadata": {},
   "outputs": [],
   "source": [
    "def chunk_by_sentence(text, max_sentences_per_chunk=5, overlap_sentences=1):\n",
    "    sentences = re.split(r\"(?<=[.!?])\\s+\", text)\n",
    "    chunks = []\n",
    "    start_idx = 0\n",
    "    len_sentences = len(sentences)\n",
    "\n",
    "    while start_idx < len_sentences:\n",
    "        end_idx = min(start_idx + max_sentences_per_chunk, len_sentences)\n",
    "        chunk = sentences[start_idx : end_idx]\n",
    "        chunks.append(\" \".join(chunk))\n",
    "\n",
    "        start_idx += max_sentences_per_chunk - overlap_sentences\n",
    "\n",
    "        if start_idx < 0:\n",
    "            start_idx = 0\n",
    "\n",
    "    return chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "e4a03fe5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "len of chunks: 33\n",
      "Chunks by structure:\n",
      "==================== Chunk 1 ====================\n",
      "# **Annual Interdisciplinary Research Review: Cross-Domain Insights**\n",
      "\n",
      "## Executive Summary\n",
      "\n",
      "This report synthesizes the key findings and ongoing research efforts across the organization's diverse operational and R&D departments for the past fiscal year. Our strength lies in the cross-pollination of ideas and methodologies, driving innovation and addressing complex challenges that transcend traditional disciplinary boundaries. This year's review highlights significant progress in ten critical areas. Advances in **Medical Research** focused on the rare XDR-471 syndrome, yielding new diagnostic insights. Concurrently, **Software Engineering** tackled persistent stability issues, implementing key fixes identified through error code analysis (e.g., `ERR_MEM_ALLOC_FAIL_0x8007000E`).\n",
      "==================== Chunk 2 ====================\n",
      "Concurrently, **Software Engineering** tackled persistent stability issues, implementing key fixes identified through error code analysis (e.g., `ERR_MEM_ALLOC_FAIL_0x8007000E`). **Financial Analysis** revealed mixed quarterly performance, prompting strategic reviews, particularly concerning resource allocation impacting R&D pipelines. Crucial developments were also seen in **Scientific Experimentation**, where novel material properties were characterized, potentially impacting future product lines. Our **Legal Developments** team navigated complex precedents, particularly in intellectual property related to the _Synergy Dynamics_ case, ensuring compliance and mitigating risk. **Product Engineering** finalized specifications for the next-generation Model Zircon-5, incorporating feedback from multiple teams.\n",
      "==================== Chunk 3 ====================\n",
      "**Product Engineering** finalized specifications for the next-generation Model Zircon-5, incorporating feedback from multiple teams. Insights from **Historical Research** into the Galveston Accords provided unexpected context for current market dynamics. **Project Management** successfully navigated critical phases for Project Cerberus despite resource constraints, documented through detailed progress reports. **Pharmaceutical Development** advanced Compound CTX-204b into further testing based on promising biomarker results. Finally, **Cybersecurity Analysis** addressed sophisticated threats, reinforcing our defenses based on detailed incident forensics.\n",
      "==================== Chunk 4 ====================\n",
      "Finally, **Cybersecurity Analysis** addressed sophisticated threats, reinforcing our defenses based on detailed incident forensics. These collective efforts underscore the value of our integrated approach. ## Table of Contents\n",
      "\n",
      "1. Executive Summary\n",
      "2. Table of Contents\n",
      "3.\n",
      "==================== Chunk 5 ====================\n",
      "Table of Contents\n",
      "3. Methodology\n",
      "4. Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "5. Section 2: Software Engineering - Project Phoenix Stability Enhancements\n",
      "6. Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "7.\n",
      "==================== Chunk 6 ====================\n",
      "Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "7. Section 4: Scientific Experimentation - Characterization of Material Composite XT-5\n",
      "8. Section 5: Legal Developments - Navigating IP Precedents and Regulatory Shifts\n",
      "9. Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "10. Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "11.\n",
      "==================== Chunk 7 ====================\n",
      "Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "11. Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "12. Section 9: Pharmaceutical Development - Compound CTX-204b Phase IIa Update\n",
      "13. Section 10: Cybersecurity Analysis - Incident Response Report\n",
      "14. Future Directions\n",
      "\n",
      "## Methodology\n",
      "\n",
      "The insights compiled within this Annual Interdisciplinary Research Review represent a synthesis of findings drawn from standard departmental reporting cycles, specialized project updates, and cross-functional review meetings conducted throughout the year.\n",
      "==================== Chunk 8 ====================\n",
      "Future Directions\n",
      "\n",
      "## Methodology\n",
      "\n",
      "The insights compiled within this Annual Interdisciplinary Research Review represent a synthesis of findings drawn from standard departmental reporting cycles, specialized project updates, and cross-functional review meetings conducted throughout the year. Data sources included internal project databases, laboratory notebooks, financial reporting systems, legal case summaries, security incident logs, and minutes from dedicated working groups. A central review committee, comprising representatives nominated by each division head, was tasked with identifying key developments and potential cross-domain implications. This committee utilized a standardized reporting template to capture essential details, including unique identifiers (project codes, error numbers, case references, etc.) and progress metrics. Subsequent analysis focused on identifying thematic overlaps, shared challenges, and opportunities for synergistic development, forming the basis of this consolidated report.\n",
      "==================== Chunk 9 ====================\n",
      "Subsequent analysis focused on identifying thematic overlaps, shared challenges, and opportunities for synergistic development, forming the basis of this consolidated report. The ambiguous references employed reflect the internal context and assume reader familiarity with ongoing initiatives and personnel. ## Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "\n",
      "This year saw significant strides in our understanding of XDR-471 syndrome, a rare neurodegenerative condition previously hampered by diagnostic ambiguity. The team focused on correlating clinical presentations with specific genetic markers, particularly variations within the Gene LOC73b region. Analysis of patient cohort data (Cohort ID: XDR-EU-03) revealed a statistically significant link between symptom severity and marker expression levels, measured via quantitative PCR assays.\n",
      "==================== Chunk 10 ====================\n",
      "Analysis of patient cohort data (Cohort ID: XDR-EU-03) revealed a statistically significant link between symptom severity and marker expression levels, measured via quantitative PCR assays. Preliminary work on a novel diagnostic biomarker panel (Panel ID: XDR-BioMk-v2) shows promise, achieving >85% sensitivity in early validation sets. However, specificity remains a challenge requiring further refinement. Ongoing efforts under Trial ID: XDR-TR002 are exploring targeted therapeutic interventions based on these findings. These results provide a much-needed foundation for future clinical strategies, though the resource implications highlighted in Section 3 (Financial Analysis) may impact the pace of subsequent trial phases.\n",
      "==================== Chunk 11 ====================\n",
      "These results provide a much-needed foundation for future clinical strategies, though the resource implications highlighted in Section 3 (Financial Analysis) may impact the pace of subsequent trial phases. The team continues to refine diagnostic protocols based on this evolving understanding. ## Section 2: Software Engineering - Project Phoenix Stability Enhancements\n",
      "\n",
      "The Software Engineering division dedicated considerable effort to improving the stability and performance of the core systems underpinning Project Phoenix. Recurring issues, particularly `ERR_MEM_ALLOC_FAIL_0x8007000E` during peak loads and `TIMEOUT_QUERY_DB_0xDEADBEEF` affecting data retrieval operations, were prioritized, at a cost of INC-2023-Q4-011. Root cause analysis pointed towards inefficiencies in the primary data caching algorithm and suboptimal database indexing strategies.\n",
      "==================== Chunk 12 ====================\n",
      "Root cause analysis pointed towards inefficiencies in the primary data caching algorithm and suboptimal database indexing strategies. The deployment of a patch addressed the memory allocation error, resulting in a measured 40% reduction in critical failures under simulated stress tests during Q4 2024 (Test Case ID: INC-2023-Q4-011). Further refactoring of the query module, scheduled for the next release cycle, aims to resolve the timeout issue. These findings underscore the importance of robust testing protocols, especially given the dependencies identified by the Product Engineering team (Section 6). The team continues to monitor system telemetry closely for any regressions or newly emerging error patterns.\n",
      "==================== Chunk 13 ====================\n",
      "The team continues to monitor system telemetry closely for any regressions or newly emerging error patterns. During Q4 of 2024 the team also assisted with helping regarding the INC-2023-Q4-011 incident. ## Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "\n",
      "Quarterly financial analysis revealed a complex picture. Overall group revenue saw modest growth of 3.1% year-over-year, primarily driven by strong performance in the primary subsidiary's established markets. However, the emerging markets division experienced a slight contraction (-1.5%), attributed to increased competitive pressure and unfavorable currency fluctuations.\n",
      "==================== Chunk 14 ====================\n",
      "However, the emerging markets division experienced a slight contraction (-1.5%), attributed to increased competitive pressure and unfavorable currency fluctuations. Margin erosion was observed across several key product lines, linked to rising input costs and supply chain disruptions. Project Hercules, aimed at optimizing operational expenditures, yielded initial savings, but these were insufficient to fully offset the margin pressure. Investment in R&D initiatives, including those detailed in Section 9 (Pharmaceutical Development) and Section 4 (Scientific Experimentation), remained stable but faces potential review in light of these pressures. The team recommends a cautious outlook, emphasizing cost control and strategic resource allocation to protect core profitability while sustaining critical innovation pipelines.\n",
      "==================== Chunk 15 ====================\n",
      "The team recommends a cautious outlook, emphasizing cost control and strategic resource allocation to protect core profitability while sustaining critical innovation pipelines. Further analysis is underway to model different investment scenarios. ## Section 4: Scientific Experimentation - Characterization of Material Composite XT-5\n",
      "\n",
      "The materials science team completed the initial characterization phase for Material Composite XT-5, a novel polymer-matrix composite developed in-house (Lab Ref: MSC-XT5-Batch007). Extensive testing focused on mechanical and thermal properties critical for potential next-generation applications. Results indicate a superior tensile strength averaging 450 ± 15 MPa, exceeding the benchmark material by approximately 18%.\n",
      "==================== Chunk 16 ====================\n",
      "Results indicate a superior tensile strength averaging 450 ± 15 MPa, exceeding the benchmark material by approximately 18%. Thermal conductivity was measured at 0.8 ± 0.05 W/(m·K), suggesting suitability for applications requiring effective thermal management. However, preliminary fatigue testing (Cycle Count: 10^5 cycles, Stress Level: 200 MPa) revealed micro-fracturing patterns requiring further investigation. This approach to rigorous characterization is vital before considering integration into designs like those discussed in Section 6 (Product Engineering). The team is now focusing on optimizing the composite matrix formulation (Variant XT-5b) to enhance fatigue resistance while maintaining other desirable properties.\n",
      "==================== Chunk 17 ====================\n",
      "The team is now focusing on optimizing the composite matrix formulation (Variant XT-5b) to enhance fatigue resistance while maintaining other desirable properties. These findings are promising but necessitate further validation. ## Section 5: Legal Developments - Navigating IP Precedents and Regulatory Shifts\n",
      "\n",
      "The Legal department actively monitored and responded to several key developments this year. The ruling in _Synergy Dynamics v. Apex Solutions_ (Docket `CV-23-1101`) established a narrower interpretation of patent eligibility for certain software-implemented inventions, requiring a review of our current IP portfolio and filing strategy.\n",
      "==================== Chunk 18 ====================\n",
      "Apex Solutions_ (Docket `CV-23-1101`) established a narrower interpretation of patent eligibility for certain software-implemented inventions, requiring a review of our current IP portfolio and filing strategy. Our team proactively identified potentially affected patents (Portfolio Segment ID: SW-PAT-CORE) and initiated amendments where necessary. Furthermore, ongoing efforts related to Project `GDPR-Audit-PhaseII` ensured continued compliance with evolving data privacy regulations, particularly concerning cross-border data transfers impacting research collaborations noted in Section 1 (Medical Research) and Section 9 (Pharmaceutical Development). A new internal framework (Policy Ref: `LEG-DP-FRMK-v3`) was implemented to streamline compliance processes. These legal precedents and regulatory shifts necessitate continuous vigilance and adaptation to mitigate risk and protect the organization's intellectual assets and operational integrity.\n",
      "==================== Chunk 19 ====================\n",
      "These legal precedents and regulatory shifts necessitate continuous vigilance and adaptation to mitigate risk and protect the organization's intellectual assets and operational integrity. The team continues to assess the impact of these developments. ## Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "\n",
      "The Product Engineering team reached a critical milestone with the finalization of core specifications for the upcoming Model Zircon-5 platform. Key performance targets have been validated on the Phase 3 prototype (Prototype ID: Z5-P3-Unit004). Confirmed specifications include a `CPU Clock Speed: 3.8 GHz (Boost)` and `System Memory: 32GB LPDDR5X`.\n",
      "==================== Chunk 20 ====================\n",
      "Confirmed specifications include a `CPU Clock Speed: 3.8 GHz (Boost)` and `System Memory: 32GB LPDDR5X`. Component `PRT-0451-C`, the primary controller sourced externally, met all reliability requirements during extended testing. Power consumption benchmarks were established at `Idle 15W / Load 75W (Typical)`, meeting design goals. Integration challenges highlighted by early software builds, potentially related to issues discussed in Section 2 (Software Engineering), necessitated minor adjustments to the board layout (Revision: Z5-MB-Rev3.1). The potential use of Material Composite XT-5, discussed in Section 4 (Scientific Experimentation), is being evaluated for the chassis design in future revisions to improve durability and thermal performance.\n",
      "==================== Chunk 21 ====================\n",
      "The potential use of Material Composite XT-5, discussed in Section 4 (Scientific Experimentation), is being evaluated for the chassis design in future revisions to improve durability and thermal performance. The design freeze enables progression to pre-production tooling. ## Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "\n",
      "Our Historical Research unit undertook a focused analysis of the economic consequences stemming from the Galveston Accords of 1921. Previous interpretations often emphasized the immediate political stabilization achieved. However, by cross-referencing diplomatic cables (Archive Ref: HRC/1921/DIP/045) with newly digitized trade ledgers (Data Set ID: `GALV-TRADE-1920s`), our team uncovered evidence of significant, previously underestimated, disruption to specific commodity markets.\n",
      "==================== Chunk 22 ====================\n",
      "However, by cross-referencing diplomatic cables (Archive Ref: HRC/1921/DIP/045) with newly digitized trade ledgers (Data Set ID: `GALV-TRADE-1920s`), our team uncovered evidence of significant, previously underestimated, disruption to specific commodity markets. The implementation clauses, particularly Annex B, appear to have created unintended barriers favoring established incumbents, hindering smaller players for nearly a decade. This revised perspective challenges the prevailing interpretation of the Accords as universally beneficial in the medium term. These findings offer a nuanced historical parallel relevant to contemporary discussions around international trade agreements and their unforeseen economic impacts, potentially informing strategies considered by the Financial Analysis team (Section 3). Further analysis is focused on tracing the long-term capital flow shifts documented in `Doc Ref: GA/1921/FIN/007`.\n",
      "==================== Chunk 23 ====================\n",
      "Further analysis is focused on tracing the long-term capital flow shifts documented in `Doc Ref: GA/1921/FIN/007`. ## Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "\n",
      "Project Cerberus successfully passed its Phase 2 Gate Review, albeit with adjustments to the original timeline. The core deliverables for Phase 2B, focusing on system integration and initial user acceptance testing (UAT), are largely complete. Team leads (J.P., K.L.) reported high fidelity in module integration, meeting 90% of the defined interface specifications (Spec Doc ID: `CERB-INT-SPEC-v2.1`). A key risk identified in the register (`Risk-CB-018: External Dependency Delay`) materialized, impacting the delivery schedule by approximately three weeks.\n",
      "==================== Chunk 24 ====================\n",
      "A key risk identified in the register (`Risk-CB-018: External Dependency Delay`) materialized, impacting the delivery schedule by approximately three weeks. Mitigation efforts led by D.M. successfully renegotiated dependencies, minimizing further slippage. Resource constraints, noted across several departments including those mentioned in Section 3 (Financial Analysis), required careful prioritization of remaining tasks. The revised timeline projects Phase 3 commencement early next quarter.\n",
      "==================== Chunk 25 ====================\n",
      "The revised timeline projects Phase 3 commencement early next quarter. This progress, despite challenges, reflects the team's adaptability and adherence to structured project management methodologies. The focus now shifts to finalizing UAT and preparing for the next phase. ## Section 9: Pharmaceutical Development - Compound CTX-204b Phase IIa Update\n",
      "\n",
      "Promising results emerged from the Phase IIa clinical trial (`Trial ID: CTX204b-P2A-001`) for Compound CTX-204b, our lead candidate targeting Receptor Pathway Gamma-7. Interim analysis of data from the initial patient cohort (n=30) demonstrated statistically significant modulation of the primary efficacy biomarker, `BioMkr-HGF`, compared to placebo (p=0.015).\n",
      "==================== Chunk 26 ====================\n",
      "Interim analysis of data from the initial patient cohort (n=30) demonstrated statistically significant modulation of the primary efficacy biomarker, `BioMkr-HGF`, compared to placebo (p=0.015). The safety profile remains generally consistent with Phase I findings, although a slightly higher incidence of mild gastrointestinal adverse events was noted (AE Code: `CTX-GI-002`), requiring ongoing monitoring. These findings support progression to dose-range finding studies. The regulatory pathway, potentially influenced by legal interpretations discussed in Section 5 (Legal Developments), is being carefully mapped. Unlike the broad diagnostic challenges seen in XDR-471 syndrome research (Section 1), CTX-204b benefits from a well-defined target population and biomarker strategy.\n",
      "==================== Chunk 27 ====================\n",
      "Unlike the broad diagnostic challenges seen in XDR-471 syndrome research (Section 1), CTX-204b benefits from a well-defined target population and biomarker strategy. The team is preparing documentation for regulatory consultation based on these interim results (Report ID: `CTX204b-P2A-INT-01`). ## Section 10: Cybersecurity Analysis - Incident Response Report: INC-2023-Q4-011\n",
      "\n",
      "The Cybersecurity Operations Center successfully contained and remediated a targeted intrusion attempt tracked as `INC-2023-Q4-011`. Threat intelligence indicates the activity aligns with tactics, techniques, and procedures associated with the `ShadowNet Syndicate` threat actor group. Initial access was gained via a spear-phishing email targeting personnel within the finance department, potentially seeking data relevant to Section 3 (Financial Analysis).\n",
      "==================== Chunk 28 ====================\n",
      "Initial access was gained via a spear-phishing email targeting personnel within the finance department, potentially seeking data relevant to Section 3 (Financial Analysis). Endpoint detection and response (EDR) systems flagged anomalous process execution (`PID: 7812`) on workstation `WS-FIN-112`. Subsequent investigation identified malware (`SHA256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855`) attempting lateral movement towards server `SRV-FIN-03`. Containment involved isolating affected systems and blocking associated command-and-control infrastructure (IP `198.51.100.24`). Mitigation included deploying updated endpoint policies and implementing enhanced perimeter filtering (`Firewall Rule ID: FN7832`).\n",
      "==================== Chunk 29 ====================\n",
      "Mitigation included deploying updated endpoint policies and implementing enhanced perimeter filtering (`Firewall Rule ID: FN7832`). This incident highlights the persistent threat landscape and the need for ongoing vigilance and user training, particularly concerning sensitive financial and potentially research data (e.g., Section 1, Section 9). Forensics analysis is ongoing. ## Future Directions\n",
      "\n",
      "This year's cross-domain insights underscore the interconnectedness of our diverse research and operational activities. The stability enhancements achieved in Software Engineering (Section 2) directly impact the reliability of platforms used in Product Engineering (Section 6) and potentially data analysis across medical and pharmaceutical research (Section 1, Section 9).\n",
      "==================== Chunk 30 ====================\n",
      "The stability enhancements achieved in Software Engineering (Section 2) directly impact the reliability of platforms used in Product Engineering (Section 6) and potentially data analysis across medical and pharmaceutical research (Section 1, Section 9). Financial constraints (Section 3) necessitate careful prioritization, potentially influencing the pace of scientific discovery (Section 4) and project timelines (Section 8). Legal and regulatory landscapes (Section 5) continue to shape our approach to intellectual property, data privacy, and clinical development (Section 9). Moving forward, fostering even greater synergy will be crucial. We propose establishing cross-functional task forces focused on:\n",
      "\n",
      "1.\n",
      "==================== Chunk 31 ====================\n",
      "We propose establishing cross-functional task forces focused on:\n",
      "\n",
      "1. **Data Integration & Security:** Leveraging cybersecurity findings (Section 10) to enhance data protection across sensitive research areas (Medical, Pharma) and ensure robust compliance frameworks informed by legal analysis (Section 5). 2. **Materials & Product Innovation:** Directly linking scientific experimentation on novel materials (Section 4) with the design requirements and testing protocols of Product Engineering (Section 6) to accelerate innovation cycles. 3.\n",
      "==================== Chunk 32 ====================\n",
      "3. **Resource Optimization & Risk Management:** Combining Financial Analysis (Section 3) with Project Management (Section 8) insights to develop more dynamic resource allocation models that better anticipate and mitigate risks identified across different domains. 4. **Historical Context & Strategic Foresight:** Utilizing insights from Historical Research (Section 7) to provide deeper context for current market dynamics and long-term strategic planning, complementing financial and legal assessments. By consciously connecting these threads, we can amplify the impact of individual departmental successes and navigate complex challenges more effectively, ensuring the organization remains at the forefront of innovation and operational excellence.\n",
      "==================== Chunk 33 ====================\n",
      "By consciously connecting these threads, we can amplify the impact of individual departmental successes and navigate complex challenges more effectively, ensuring the organization remains at the forefront of innovation and operational excellence. The findings presented in this review provide a solid foundation for these future collaborative efforts. \n"
     ]
    }
   ],
   "source": [
    "with open(\"./assets/report.md\", \"r\") as f:\n",
    "    text = f.read()\n",
    "\n",
    "chunks = chunk_by_sentence(text)\n",
    "\n",
    "print(f\"len of chunks: {len(chunks)}\")\n",
    "print(\"Chunks by structure:\")\n",
    "for i, chunk in enumerate(chunks):\n",
    "    print(\"=\"*20, f\"Chunk {i + 1}\", \"=\"*20)\n",
    "    print(chunk)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "bdb734cb",
   "metadata": {},
   "source": [
    "## Size-based Chunking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "ffaa6bda",
   "metadata": {},
   "outputs": [],
   "source": [
    "def chunk_by_size(text, chunk_size=150, overlap_size=20):\n",
    "    chunks = []\n",
    "    start_idx = 0\n",
    "    len_text = len(text)\n",
    "\n",
    "    while start_idx < len_text:\n",
    "        end_idx = min(start_idx + chunk_size, len_text)\n",
    "        chunk = text[start_idx : end_idx]\n",
    "        chunks.append(chunk)\n",
    "\n",
    "        start_idx += chunk_size - overlap_size\n",
    "\n",
    "        if start_idx < 0:\n",
    "            start_idx = 0\n",
    "    \n",
    "    return chunks"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "8208820d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "len of chunks: 141\n",
      "Chunks by structure:\n",
      "==================== Chunk 1 ====================\n",
      "# **Annual Interdisciplinary Research Review: Cross-Domain Insights**\n",
      "\n",
      "## Executive Summary\n",
      "\n",
      "This report synthesizes the key findings and ongoing rese\n",
      "==================== Chunk 2 ====================\n",
      "ngs and ongoing research efforts across the organization's diverse operational and R&D departments for the past fiscal year. Our strength lies in the \n",
      "==================== Chunk 3 ====================\n",
      "trength lies in the cross-pollination of ideas and methodologies, driving innovation and addressing complex challenges that transcend traditional disc\n",
      "==================== Chunk 4 ====================\n",
      "end traditional disciplinary boundaries. This year's review highlights significant progress in ten critical areas. Advances in **Medical Research** fo\n",
      "==================== Chunk 5 ====================\n",
      "edical Research** focused on the rare XDR-471 syndrome, yielding new diagnostic insights. Concurrently, **Software Engineering** tackled persistent st\n",
      "==================== Chunk 6 ====================\n",
      "ackled persistent stability issues, implementing key fixes identified through error code analysis (e.g., `ERR_MEM_ALLOC_FAIL_0x8007000E`). **Financial\n",
      "==================== Chunk 7 ====================\n",
      "7000E`). **Financial Analysis** revealed mixed quarterly performance, prompting strategic reviews, particularly concerning resource allocation impacti\n",
      "==================== Chunk 8 ====================\n",
      "e allocation impacting R&D pipelines.\n",
      "\n",
      "Crucial developments were also seen in **Scientific Experimentation**, where novel material properties were cha\n",
      "==================== Chunk 9 ====================\n",
      " properties were characterized, potentially impacting future product lines. Our **Legal Developments** team navigated complex precedents, particularly\n",
      "==================== Chunk 10 ====================\n",
      "edents, particularly in intellectual property related to the _Synergy Dynamics_ case, ensuring compliance and mitigating risk. **Product Engineering**\n",
      "==================== Chunk 11 ====================\n",
      "roduct Engineering** finalized specifications for the next-generation Model Zircon-5, incorporating feedback from multiple teams. Insights from **Hist\n",
      "==================== Chunk 12 ====================\n",
      "Insights from **Historical Research** into the Galveston Accords provided unexpected context for current market dynamics. **Project Management** succe\n",
      "==================== Chunk 13 ====================\n",
      "t Management** successfully navigated critical phases for Project Cerberus despite resource constraints, documented through detailed progress reports.\n",
      "==================== Chunk 14 ====================\n",
      "ed progress reports. **Pharmaceutical Development** advanced Compound CTX-204b into further testing based on promising biomarker results. Finally, **C\n",
      "==================== Chunk 15 ====================\n",
      "esults. Finally, **Cybersecurity Analysis** addressed sophisticated threats, reinforcing our defenses based on detailed incident forensics. These coll\n",
      "==================== Chunk 16 ====================\n",
      "orensics. These collective efforts underscore the value of our integrated approach.\n",
      "\n",
      "## Table of Contents\n",
      "\n",
      "1.  Executive Summary\n",
      "2.  Table of Contents\n",
      "==================== Chunk 17 ====================\n",
      ".  Table of Contents\n",
      "3.  Methodology\n",
      "4.  Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "5.  Section 2: Software Engineering - Project Ph\n",
      "==================== Chunk 18 ====================\n",
      "neering - Project Phoenix Stability Enhancements\n",
      "6.  Section 3: Financial Analysis - Q3 Performance and Outlook\n",
      "7.  Section 4: Scientific Experimentat\n",
      "==================== Chunk 19 ====================\n",
      "entific Experimentation - Characterization of Material Composite XT-5\n",
      "8.  Section 5: Legal Developments - Navigating IP Precedents and Regulatory Shif\n",
      "==================== Chunk 20 ====================\n",
      " and Regulatory Shifts\n",
      "9.  Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "10. Section 7: Historical Research - Re-evaluatin\n",
      "==================== Chunk 21 ====================\n",
      "earch - Re-evaluating the Galveston Accords (1921)\n",
      "11. Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "12. Section 9: Pharmaceut\n",
      "==================== Chunk 22 ====================\n",
      "ection 9: Pharmaceutical Development - Compound CTX-204b Phase IIa Update\n",
      "13. Section 10: Cybersecurity Analysis - Incident Response Report\n",
      "14. Future\n",
      "==================== Chunk 23 ====================\n",
      "se Report\n",
      "14. Future Directions\n",
      "\n",
      "## Methodology\n",
      "\n",
      "The insights compiled within this Annual Interdisciplinary Research Review represent a synthesis of f\n",
      "==================== Chunk 24 ====================\n",
      "ent a synthesis of findings drawn from standard departmental reporting cycles, specialized project updates, and cross-functional review meetings condu\n",
      "==================== Chunk 25 ====================\n",
      "eview meetings conducted throughout the year. Data sources included internal project databases, laboratory notebooks, financial reporting systems, leg\n",
      "==================== Chunk 26 ====================\n",
      "porting systems, legal case summaries, security incident logs, and minutes from dedicated working groups. A central review committee, comprising repre\n",
      "==================== Chunk 27 ====================\n",
      "ee, comprising representatives nominated by each division head, was tasked with identifying key developments and potential cross-domain implications. \n",
      "==================== Chunk 28 ====================\n",
      "omain implications. This committee utilized a standardized reporting template to capture essential details, including unique identifiers (project code\n",
      "==================== Chunk 29 ====================\n",
      "ifiers (project codes, error numbers, case references, etc.) and progress metrics. Subsequent analysis focused on identifying thematic overlaps, share\n",
      "==================== Chunk 30 ====================\n",
      "atic overlaps, shared challenges, and opportunities for synergistic development, forming the basis of this consolidated report. The ambiguous referenc\n",
      "==================== Chunk 31 ====================\n",
      "e ambiguous references employed reflect the internal context and assume reader familiarity with ongoing initiatives and personnel.\n",
      "\n",
      "## Section 1: Medi\n",
      "==================== Chunk 32 ====================\n",
      "\n",
      "\n",
      "## Section 1: Medical Research - Understanding XDR-471 Syndrome\n",
      "\n",
      "This year saw significant strides in our understanding of XDR-471 syndrome, a rare \n",
      "==================== Chunk 33 ====================\n",
      "71 syndrome, a rare neurodegenerative condition previously hampered by diagnostic ambiguity. The team focused on correlating clinical presentations wi\n",
      "==================== Chunk 34 ====================\n",
      "cal presentations with specific genetic markers, particularly variations within the Gene LOC73b region. Analysis of patient cohort data (Cohort ID: XD\n",
      "==================== Chunk 35 ====================\n",
      " data (Cohort ID: XDR-EU-03) revealed a statistically significant link between symptom severity and marker expression levels, measured via quantitativ\n",
      "==================== Chunk 36 ====================\n",
      "ured via quantitative PCR assays. Preliminary work on a novel diagnostic biomarker panel (Panel ID: XDR-BioMk-v2) shows promise, achieving >85% sensit\n",
      "==================== Chunk 37 ====================\n",
      "chieving >85% sensitivity in early validation sets. However, specificity remains a challenge requiring further refinement. Ongoing efforts under Trial\n",
      "==================== Chunk 38 ====================\n",
      " efforts under Trial ID: XDR-TR002 are exploring targeted therapeutic interventions based on these findings. These results provide a much-needed found\n",
      "==================== Chunk 39 ====================\n",
      " a much-needed foundation for future clinical strategies, though the resource implications highlighted in Section 3 (Financial Analysis) may impact th\n",
      "==================== Chunk 40 ====================\n",
      "lysis) may impact the pace of subsequent trial phases. The team continues to refine diagnostic protocols based on this evolving understanding.\n",
      "\n",
      "## Sec\n",
      "==================== Chunk 41 ====================\n",
      "derstanding.\n",
      "\n",
      "## Section 2: Software Engineering - Project Phoenix Stability Enhancements\n",
      "\n",
      "The Software Engineering division dedicated considerable ef\n",
      "==================== Chunk 42 ====================\n",
      "ated considerable effort to improving the stability and performance of the core systems underpinning Project Phoenix. Recurring issues, particularly `\n",
      "==================== Chunk 43 ====================\n",
      "sues, particularly `ERR_MEM_ALLOC_FAIL_0x8007000E` during peak loads and `TIMEOUT_QUERY_DB_0xDEADBEEF` affecting data retrieval operations, were prior\n",
      "==================== Chunk 44 ====================\n",
      "erations, were prioritized, at a cost of INC-2023-Q4-011. Root cause analysis pointed towards inefficiencies in the primary data caching algorithm and\n",
      "==================== Chunk 45 ====================\n",
      "aching algorithm and suboptimal database indexing strategies. The deployment of a patch addressed the memory allocation error, resulting in a measured\n",
      "==================== Chunk 46 ====================\n",
      "ulting in a measured 40% reduction in critical failures under simulated stress tests during Q4 2024 (Test Case ID: INC-2023-Q4-011). Further refactori\n",
      "==================== Chunk 47 ====================\n",
      "). Further refactoring of the query module, scheduled for the next release cycle, aims to resolve the timeout issue. These findings underscore the imp\n",
      "==================== Chunk 48 ====================\n",
      "s underscore the importance of robust testing protocols, especially given the dependencies identified by the Product Engineering team (Section 6). The\n",
      "==================== Chunk 49 ====================\n",
      "eam (Section 6). The team continues to monitor system telemetry closely for any regressions or newly emerging error patterns. During Q4 of 2024 the te\n",
      "==================== Chunk 50 ====================\n",
      "ng Q4 of 2024 the team also assisted with helping regarding the INC-2023-Q4-011 incident.\n",
      "\n",
      "## Section 3: Financial Analysis - Q3 Performance and Outlo\n",
      "==================== Chunk 51 ====================\n",
      "erformance and Outlook\n",
      "\n",
      "Quarterly financial analysis revealed a complex picture. Overall group revenue saw modest growth of 3.1% year-over-year, prima\n",
      "==================== Chunk 52 ====================\n",
      "ear-over-year, primarily driven by strong performance in the primary subsidiary's established markets. However, the emerging markets division experien\n",
      "==================== Chunk 53 ====================\n",
      "ts division experienced a slight contraction (-1.5%), attributed to increased competitive pressure and unfavorable currency fluctuations. Margin erosi\n",
      "==================== Chunk 54 ====================\n",
      "ations. Margin erosion was observed across several key product lines, linked to rising input costs and supply chain disruptions. Project Hercules, aim\n",
      "==================== Chunk 55 ====================\n",
      "roject Hercules, aimed at optimizing operational expenditures, yielded initial savings, but these were insufficient to fully offset the margin pressur\n",
      "==================== Chunk 56 ====================\n",
      "t the margin pressure. Investment in R&D initiatives, including those detailed in Section 9 (Pharmaceutical Development) and Section 4 (Scientific Exp\n",
      "==================== Chunk 57 ====================\n",
      "on 4 (Scientific Experimentation), remained stable but faces potential review in light of these pressures. The team recommends a cautious outlook, emp\n",
      "==================== Chunk 58 ====================\n",
      "autious outlook, emphasizing cost control and strategic resource allocation to protect core profitability while sustaining critical innovation pipelin\n",
      "==================== Chunk 59 ====================\n",
      "l innovation pipelines. Further analysis is underway to model different investment scenarios.\n",
      "\n",
      "## Section 4: Scientific Experimentation - Characteriza\n",
      "==================== Chunk 60 ====================\n",
      "ation - Characterization of Material Composite XT-5\n",
      "\n",
      "The materials science team completed the initial characterization phase for Material Composite XT\n",
      "==================== Chunk 61 ====================\n",
      "aterial Composite XT-5, a novel polymer-matrix composite developed in-house (Lab Ref: MSC-XT5-Batch007). Extensive testing focused on mechanical and t\n",
      "==================== Chunk 62 ====================\n",
      " on mechanical and thermal properties critical for potential next-generation applications. Results indicate a superior tensile strength averaging 450 \n",
      "==================== Chunk 63 ====================\n",
      "ength averaging 450 ± 15 MPa, exceeding the benchmark material by approximately 18%. Thermal conductivity was measured at 0.8 ± 0.05 W/(m·K), suggesti\n",
      "==================== Chunk 64 ====================\n",
      "05 W/(m·K), suggesting suitability for applications requiring effective thermal management. However, preliminary fatigue testing (Cycle Count: 10^5 cy\n",
      "==================== Chunk 65 ====================\n",
      "Cycle Count: 10^5 cycles, Stress Level: 200 MPa) revealed micro-fracturing patterns requiring further investigation. This approach to rigorous charact\n",
      "==================== Chunk 66 ====================\n",
      " to rigorous characterization is vital before considering integration into designs like those discussed in Section 6 (Product Engineering). The team i\n",
      "==================== Chunk 67 ====================\n",
      "neering). The team is now focusing on optimizing the composite matrix formulation (Variant XT-5b) to enhance fatigue resistance while maintaining othe\n",
      "==================== Chunk 68 ====================\n",
      "ile maintaining other desirable properties. These findings are promising but necessitate further validation.\n",
      "\n",
      "## Section 5: Legal Developments - Navig\n",
      "==================== Chunk 69 ====================\n",
      "Developments - Navigating IP Precedents and Regulatory Shifts\n",
      "\n",
      "The Legal department actively monitored and responded to several key developments this \n",
      "==================== Chunk 70 ====================\n",
      "y developments this year. The ruling in _Synergy Dynamics v. Apex Solutions_ (Docket `CV-23-1101`) established a narrower interpretation of patent eli\n",
      "==================== Chunk 71 ====================\n",
      "tation of patent eligibility for certain software-implemented inventions, requiring a review of our current IP portfolio and filing strategy. Our team\n",
      "==================== Chunk 72 ====================\n",
      "g strategy. Our team proactively identified potentially affected patents (Portfolio Segment ID: SW-PAT-CORE) and initiated amendments where necessary.\n",
      "==================== Chunk 73 ====================\n",
      "nts where necessary. Furthermore, ongoing efforts related to Project `GDPR-Audit-PhaseII` ensured continued compliance with evolving data privacy regu\n",
      "==================== Chunk 74 ====================\n",
      "ng data privacy regulations, particularly concerning cross-border data transfers impacting research collaborations noted in Section 1 (Medical Researc\n",
      "==================== Chunk 75 ====================\n",
      "n 1 (Medical Research) and Section 9 (Pharmaceutical Development). A new internal framework (Policy Ref: `LEG-DP-FRMK-v3`) was implemented to streamli\n",
      "==================== Chunk 76 ====================\n",
      "lemented to streamline compliance processes. These legal precedents and regulatory shifts necessitate continuous vigilance and adaptation to mitigate \n",
      "==================== Chunk 77 ====================\n",
      "ptation to mitigate risk and protect the organization's intellectual assets and operational integrity. The team continues to assess the impact of thes\n",
      "==================== Chunk 78 ====================\n",
      "s the impact of these developments.\n",
      "\n",
      "## Section 6: Product Engineering - Finalizing Model Zircon-5 Specifications\n",
      "\n",
      "The Product Engineering team reache\n",
      "==================== Chunk 79 ====================\n",
      "ineering team reached a critical milestone with the finalization of core specifications for the upcoming Model Zircon-5 platform. Key performance targ\n",
      "==================== Chunk 80 ====================\n",
      "Key performance targets have been validated on the Phase 3 prototype (Prototype ID: Z5-P3-Unit004). Confirmed specifications include a `CPU Clock Spee\n",
      "==================== Chunk 81 ====================\n",
      "de a `CPU Clock Speed: 3.8 GHz (Boost)` and `System Memory: 32GB LPDDR5X`. Component `PRT-0451-C`, the primary controller sourced externally, met all \n",
      "==================== Chunk 82 ====================\n",
      "externally, met all reliability requirements during extended testing. Power consumption benchmarks were established at `Idle 15W / Load 75W (Typical)`\n",
      "==================== Chunk 83 ====================\n",
      " Load 75W (Typical)`, meeting design goals. Integration challenges highlighted by early software builds, potentially related to issues discussed in Se\n",
      "==================== Chunk 84 ====================\n",
      "sues discussed in Section 2 (Software Engineering), necessitated minor adjustments to the board layout (Revision: Z5-MB-Rev3.1). The potential use of \n",
      "==================== Chunk 85 ====================\n",
      "he potential use of Material Composite XT-5, discussed in Section 4 (Scientific Experimentation), is being evaluated for the chassis design in future \n",
      "==================== Chunk 86 ====================\n",
      "is design in future revisions to improve durability and thermal performance. The design freeze enables progression to pre-production tooling.\n",
      "\n",
      "## Sect\n",
      "==================== Chunk 87 ====================\n",
      "on tooling.\n",
      "\n",
      "## Section 7: Historical Research - Re-evaluating the Galveston Accords (1921)\n",
      "\n",
      "Our Historical Research unit undertook a focused analysis\n",
      "==================== Chunk 88 ====================\n",
      "k a focused analysis of the economic consequences stemming from the Galveston Accords of 1921. Previous interpretations often emphasized the immediate\n",
      "==================== Chunk 89 ====================\n",
      "asized the immediate political stabilization achieved. However, by cross-referencing diplomatic cables (Archive Ref: HRC/1921/DIP/045) with newly digi\n",
      "==================== Chunk 90 ====================\n",
      "045) with newly digitized trade ledgers (Data Set ID: `GALV-TRADE-1920s`), our team uncovered evidence of significant, previously underestimated, disr\n",
      "==================== Chunk 91 ====================\n",
      "underestimated, disruption to specific commodity markets. The implementation clauses, particularly Annex B, appear to have created unintended barriers\n",
      "==================== Chunk 92 ====================\n",
      " unintended barriers favoring established incumbents, hindering smaller players for nearly a decade. This revised perspective challenges the prevailin\n",
      "==================== Chunk 93 ====================\n",
      "lenges the prevailing interpretation of the Accords as universally beneficial in the medium term. These findings offer a nuanced historical parallel r\n",
      "==================== Chunk 94 ====================\n",
      "istorical parallel relevant to contemporary discussions around international trade agreements and their unforeseen economic impacts, potentially infor\n",
      "==================== Chunk 95 ====================\n",
      "s, potentially informing strategies considered by the Financial Analysis team (Section 3). Further analysis is focused on tracing the long-term capita\n",
      "==================== Chunk 96 ====================\n",
      "the long-term capital flow shifts documented in `Doc Ref: GA/1921/FIN/007`.\n",
      "\n",
      "## Section 8: Project Management - Progress on Project Cerberus Phase 2B\n",
      "\n",
      "==================== Chunk 97 ====================\n",
      "t Cerberus Phase 2B\n",
      "\n",
      "Project Cerberus successfully passed its Phase 2 Gate Review, albeit with adjustments to the original timeline. The core delivera\n",
      "==================== Chunk 98 ====================\n",
      "e. The core deliverables for Phase 2B, focusing on system integration and initial user acceptance testing (UAT), are largely complete. Team leads (J.P\n",
      "==================== Chunk 99 ====================\n",
      "ete. Team leads (J.P., K.L.) reported high fidelity in module integration, meeting 90% of the defined interface specifications (Spec Doc ID: `CERB-INT\n",
      "==================== Chunk 100 ====================\n",
      "ec Doc ID: `CERB-INT-SPEC-v2.1`). A key risk identified in the register (`Risk-CB-018: External Dependency Delay`) materialized, impacting the deliver\n",
      "==================== Chunk 101 ====================\n",
      "mpacting the delivery schedule by approximately three weeks. Mitigation efforts led by D.M. successfully renegotiated dependencies, minimizing further\n",
      "==================== Chunk 102 ====================\n",
      ", minimizing further slippage. Resource constraints, noted across several departments including those mentioned in Section 3 (Financial Analysis), req\n",
      "==================== Chunk 103 ====================\n",
      "ncial Analysis), required careful prioritization of remaining tasks. The revised timeline projects Phase 3 commencement early next quarter. This progr\n",
      "==================== Chunk 104 ====================\n",
      " quarter. This progress, despite challenges, reflects the team's adaptability and adherence to structured project management methodologies. The focus \n",
      "==================== Chunk 105 ====================\n",
      "dologies. The focus now shifts to finalizing UAT and preparing for the next phase.\n",
      "\n",
      "## Section 9: Pharmaceutical Development - Compound CTX-204b Phase\n",
      "==================== Chunk 106 ====================\n",
      "pound CTX-204b Phase IIa Update\n",
      "\n",
      "Promising results emerged from the Phase IIa clinical trial (`Trial ID: CTX204b-P2A-001`) for Compound CTX-204b, our \n",
      "==================== Chunk 107 ====================\n",
      "pound CTX-204b, our lead candidate targeting Receptor Pathway Gamma-7. Interim analysis of data from the initial patient cohort (n=30) demonstrated st\n",
      "==================== Chunk 108 ====================\n",
      "=30) demonstrated statistically significant modulation of the primary efficacy biomarker, `BioMkr-HGF`, compared to placebo (p=0.015). The safety prof\n",
      "==================== Chunk 109 ====================\n",
      "15). The safety profile remains generally consistent with Phase I findings, although a slightly higher incidence of mild gastrointestinal adverse even\n",
      "==================== Chunk 110 ====================\n",
      "estinal adverse events was noted (AE Code: `CTX-GI-002`), requiring ongoing monitoring. These findings support progression to dose-range finding studi\n",
      "==================== Chunk 111 ====================\n",
      "-range finding studies. The regulatory pathway, potentially influenced by legal interpretations discussed in Section 5 (Legal Developments), is being \n",
      "==================== Chunk 112 ====================\n",
      "lopments), is being carefully mapped. Unlike the broad diagnostic challenges seen in XDR-471 syndrome research (Section 1), CTX-204b benefits from a w\n",
      "==================== Chunk 113 ====================\n",
      "4b benefits from a well-defined target population and biomarker strategy. The team is preparing documentation for regulatory consultation based on the\n",
      "==================== Chunk 114 ====================\n",
      "ltation based on these interim results (Report ID: `CTX204b-P2A-INT-01`).\n",
      "\n",
      "## Section 10: Cybersecurity Analysis - Incident Response Report: INC-2023-\n",
      "==================== Chunk 115 ====================\n",
      "se Report: INC-2023-Q4-011\n",
      "\n",
      "The Cybersecurity Operations Center successfully contained and remediated a targeted intrusion attempt tracked as `INC-202\n",
      "==================== Chunk 116 ====================\n",
      " tracked as `INC-2023-Q4-011`. Threat intelligence indicates the activity aligns with tactics, techniques, and procedures associated with the `ShadowN\n",
      "==================== Chunk 117 ====================\n",
      "ed with the `ShadowNet Syndicate` threat actor group. Initial access was gained via a spear-phishing email targeting personnel within the finance depa\n",
      "==================== Chunk 118 ====================\n",
      "hin the finance department, potentially seeking data relevant to Section 3 (Financial Analysis). Endpoint detection and response (EDR) systems flagged\n",
      "==================== Chunk 119 ====================\n",
      "EDR) systems flagged anomalous process execution (`PID: 7812`) on workstation `WS-FIN-112`. Subsequent investigation identified malware (`SHA256:e3b0c\n",
      "==================== Chunk 120 ====================\n",
      "lware (`SHA256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855`) attempting lateral movement towards server `SRV-FIN-03`. Containment\n",
      "==================== Chunk 121 ====================\n",
      "FIN-03`. Containment involved isolating affected systems and blocking associated command-and-control infrastructure (IP `198.51.100.24`). Mitigation i\n",
      "==================== Chunk 122 ====================\n",
      "0.24`). Mitigation included deploying updated endpoint policies and implementing enhanced perimeter filtering (`Firewall Rule ID: FN7832`). This incid\n",
      "==================== Chunk 123 ====================\n",
      "FN7832`). This incident highlights the persistent threat landscape and the need for ongoing vigilance and user training, particularly concerning sensi\n",
      "==================== Chunk 124 ====================\n",
      "rly concerning sensitive financial and potentially research data (e.g., Section 1, Section 9). Forensics analysis is ongoing.\n",
      "\n",
      "## Future Directions\n",
      "\n",
      "T\n",
      "==================== Chunk 125 ====================\n",
      "Future Directions\n",
      "\n",
      "This year's cross-domain insights underscore the interconnectedness of our diverse research and operational activities. The stabili\n",
      "==================== Chunk 126 ====================\n",
      "ivities. The stability enhancements achieved in Software Engineering (Section 2) directly impact the reliability of platforms used in Product Engineer\n",
      "==================== Chunk 127 ====================\n",
      " in Product Engineering (Section 6) and potentially data analysis across medical and pharmaceutical research (Section 1, Section 9). Financial constra\n",
      "==================== Chunk 128 ====================\n",
      "). Financial constraints (Section 3) necessitate careful prioritization, potentially influencing the pace of scientific discovery (Section 4) and proj\n",
      "==================== Chunk 129 ====================\n",
      "(Section 4) and project timelines (Section 8). Legal and regulatory landscapes (Section 5) continue to shape our approach to intellectual property, da\n",
      "==================== Chunk 130 ====================\n",
      "lectual property, data privacy, and clinical development (Section 9).\n",
      "\n",
      "Moving forward, fostering even greater synergy will be crucial. We propose esta\n",
      "==================== Chunk 131 ====================\n",
      "ial. We propose establishing cross-functional task forces focused on:\n",
      "\n",
      "1.  **Data Integration & Security:** Leveraging cybersecurity findings (Section\n",
      "==================== Chunk 132 ====================\n",
      "ty findings (Section 10) to enhance data protection across sensitive research areas (Medical, Pharma) and ensure robust compliance frameworks informed\n",
      "==================== Chunk 133 ====================\n",
      " frameworks informed by legal analysis (Section 5).\n",
      "2.  **Materials & Product Innovation:** Directly linking scientific experimentation on novel mater\n",
      "==================== Chunk 134 ====================\n",
      "ation on novel materials (Section 4) with the design requirements and testing protocols of Product Engineering (Section 6) to accelerate innovation cy\n",
      "==================== Chunk 135 ====================\n",
      "lerate innovation cycles.\n",
      "3.  **Resource Optimization & Risk Management:** Combining Financial Analysis (Section 3) with Project Management (Section 8\n",
      "==================== Chunk 136 ====================\n",
      "anagement (Section 8) insights to develop more dynamic resource allocation models that better anticipate and mitigate risks identified across differen\n",
      "==================== Chunk 137 ====================\n",
      "fied across different domains.\n",
      "4.  **Historical Context & Strategic Foresight:** Utilizing insights from Historical Research (Section 7) to provide de\n",
      "==================== Chunk 138 ====================\n",
      "ion 7) to provide deeper context for current market dynamics and long-term strategic planning, complementing financial and legal assessments.\n",
      "\n",
      "By cons\n",
      "==================== Chunk 139 ====================\n",
      "ssessments.\n",
      "\n",
      "By consciously connecting these threads, we can amplify the impact of individual departmental successes and navigate complex challenges m\n",
      "==================== Chunk 140 ====================\n",
      "complex challenges more effectively, ensuring the organization remains at the forefront of innovation and operational excellence. The findings present\n",
      "==================== Chunk 141 ====================\n",
      "The findings presented in this review provide a solid foundation for these future collaborative efforts.\n",
      "\n"
     ]
    }
   ],
   "source": [
    "with open(\"./assets/report.md\", \"r\") as f:\n",
    "    text = f.read()\n",
    "\n",
    "chunks = chunk_by_size(text)\n",
    "\n",
    "print(f\"len of chunks: {len(chunks)}\")\n",
    "print(\"Chunks by structure:\")\n",
    "for i, chunk in enumerate(chunks):\n",
    "    print(\"=\"*20, f\"Chunk {i + 1}\", \"=\"*20)\n",
    "    print(chunk)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "d6cb41ca",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "HelloWorld-Claude",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
